Clinical Trials Using Autologous PSMA-specific TGFb-resistant CAR T Cells

Clinical trials are research studies that involve people. The clinical trials on this list are studying Autologous PSMA-specific TGFb-resistant CAR T Cells. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-2 of 2
  • A Study of CART-PSMA-TGFβRDN in Patients With Metastatic Castration Resistant Prostate Cancer

    Multi-center, open-label, Phase 1 study of the safety, tolerability and feasibility of dosing patients harboring metastatic castration resistant prostate cancer (mCRPC) with genetically modified autologous T cells (CART-PSMA-TGFβRDN cells) engineered to express a chimeric antigen receptor (CAR) capable of recognizing the tumor antigen prostate-specific membrane antigen (PSMA) and activating the T cell.
    Location: 3 locations

  • CART-PSMA-TGFbetaRDN Cells in Treating Patients with Metastatic Castrate Resistant Prostate Cancer

    This phase I trial studies the side effects and best dose of CART-PSMA-TGFbetaRDN cells in treating patients with castrate resistant prostate cancer that has spread to other places in the body. Biological therapies, such as CART-PSMA-TGFbetaRDN cells, use substances made from living organisms that may stimulate or suppress the immune system in different ways and stop tumor cells from growing.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania